1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Morocco Pharmaceuticals and Healthcare Report Q4 2016

Morocco Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 98 pages

Includes 3 FREE quarterly updates


BMI View: The Moroccan government's strategy of introducing pharma-clusters in an attempt to strengthen the domestic pharmaceutical industry will see the market develop into a more attractive investment destination for multinational drugmakers. The use of pharma-clusters to boost local production capabilities is an increasingly common trend across the emerging markets, yielding productivity gains and improving access to medicines on a national scale. However, additional plans to reform the regulatory and pricing system remain dubious, given the government's poor track record of successfully implementing past proposals.

Headline Expenditure Projections
- Pharmaceuticals: MAD13.39bn (USD1.37bn) in 2015 to MAD14.29bn (USD1.44bn) in 2016; +6.8% in local currency terms and +5.1% in US dollar terms. Forecast revised downwards slightly from last quarter.
- Healthcare: MAD56.70bn (USD5.81bn) in 2015 to MAD59.42bn (USD6.00bn) in 2016; +4.8% in local currency terms and +3.1% in US dollar terms. Forecast revised downwards slightly from last quarter.

Table Of Contents

Morocco Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Morocco 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2012-2020) 15
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2014-2020) 31
Pharmaceuticals and Healthcare Risk/Reward Index 32
Middle East and Africa Risk/Reward Index - Q4 2016 32
Morocco Risk/ Reward Index 40
Rewards 40
Risks 41
Regulatory Review 43
Intellectual Property Issues 44
Pricing Regime 44
Reimbursement Regime 47
Market Overview 50
Healthcare Sector 51
Table: Healthcare Resources (Morocco 2010-2015) 55
Table: Healthcare Personnel (Morocco 2010-2015) 55
Table: Healthcare Activity (Morocco 2010-2015) 56
Healthcare Insurance 56
Research and Development 60
Clinical Trials 60
Epidemiology 61
Competitive Landscape 65
Research-Based Industry 65
Table: Members Of MIS, 2011 65
Table: Members Of AMIP, 2011 66
Generic Drugmakers 66
Table: Multinational Market Activity 69
Pharmaceutical Distribution 69
Pharmaceutical Retail Sector 70
Company Profile 72
GlaxoSmithKline 72
Laprophan 74
Pfizer 77
Sanofi 80
Sothema 84
Demographic Forecast 87
Demographic Outlook 87
Table: Population Headline Indicators (Morocco 1990-2025) 88
Table: Key Population Ratios (Morocco 1990-2025) 88
Table: Urban/Rural Population and Life Expectancy (Morocco 1990-2025) 89
Table: Population By Age Group (Morocco 1990-2025) 89
Table: Population By Age Group % (Morocco 1990-2025) 90
Glossary 92
Methodology 94
Pharmaceutical Expenditure Forecast Model 94
Healthcare Expenditure Forecast Model 94
Notes On Methodology 95
Risk/Reward Index Methodology 96
Index Overview 97
Table: Pharmaceutical Risk/Reward Index Indicators 97
Indicator Weightings 98

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.